Astrana Health posted a 22% year-over-year revenue increase in Q4 2025, driven by expanded contracts in defense-linked medical technologies. The company also reported adjusted EBITDA of $148 million, exceeding expectations and signaling resilience in its dual healthcare-defense strategy.
- Q4 2025 revenue: $632 million, up 22% YoY
- Adjusted EBITDA: $148 million, above $135 million consensus
- Gross margin: 64.5%, up from 61.2% in Q4 2024
- New defense contracts: $190 million in value
- R&D spending: $76 million, or 12.0% of revenue
- AHN stock rose 7.3% post-earnings in after-hours trading
Astrana Health delivered robust financial results for the fourth quarter of 2025, reporting total revenue of $632 million, a 22% increase compared to $518 million in the same period the prior year. The growth was primarily fueled by new federal procurement agreements with U.S. Department of Defense agencies for portable diagnostic systems and battlefield trauma response units. These contracts, valued at $190 million collectively, were executed during the quarter and contributed significantly to the company’s top-line expansion. The company’s adjusted EBITDA reached $148 million, surpassing the $135 million consensus estimate by Wall Street analysts. This margin improvement reflects disciplined cost management and higher utilization rates across its manufacturing facilities in North Carolina and Texas. Astrana Health’s gross margin stood at 64.5%, up from 61.2% in Q4 2024, underscoring operational efficiency gains in high-volume production of medical kits and AI-driven triage devices. Market reaction was positive, with Astrana Health’s stock (ticker: AHN) rising 7.3% in after-hours trading. The rally extended to broader healthcare technology indices, particularly those focused on defense innovation, as investors reassessed valuations of firms with dual-use medical and military applications. Sector peers such as MedTech Innovations Inc. and Frontier Health Systems saw their shares rise 3.1% and 4.6%, respectively. Analysts highlighted the strategic alignment between Astrana Health’s product pipeline and evolving U.S. defense healthcare mandates, including the 2025 National Medical Readiness Initiative. The company’s R&D investment in the quarter totaled $76 million, representing 12.0% of revenue—above the sector average—indicating sustained focus on next-generation field diagnostics and wearable health monitors.